Inventia Life Science Unveils RASTRUM™ Allegro to Transform 3D Cell Culture in Drug Discovery and Disease Research Inventia Life Science, a leader in 3D cell culture technologies, has announced the launch of RASTRUM™ Allegro, a revolutionary platform that enhances drug…
Genentech Announces Positive OS Results for Itovebi in Advanced HR-Positive Breast Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), has announced positive topline results from the Phase III INAVO120 study investigating the combination of Itovebi™…
Cannabis Pharmaceuticals Market 2024-2034: Focus on Sativex, Cesamet, Marinol, Epidiolex – ResearchAndMarkets.com The global cannabis pharmaceuticals market, valued at USD 3.46 billion in 2023, is expected to experience remarkable growth, reaching USD 380.77 billion by 2034. This expansion is forecasted…
Salubris Biotherapeutics Announces Positive Interim Data from Phase 2 Trial of JK07 in Heart Failure Salubris Biotherapeutics a clinical-stage biotechnology company focused on developing innovative biologic therapies, has announced promising interim data from its Phase 2 clinical trial of JK07…
BrainChild Bio Receives Recognition for Innovation in Cell Therapy ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, has announced that BrainChild Bio has been awarded a $300,000 G-Rex® Grant. This prestigious grant is aimed at accelerating the…
WHO Expresses Regret Over U.S. Withdrawal Announcement The World Health Organization (WHO) has expressed deep regret over the announcement that the United States intends to withdraw from the Organization. The decision, if finalized, would mark a significant shift in global…
Poxel Achieves Milestone with TWYMEEG® Sales in Japan, Secures Royalties and Sales-Based Payments Poxel, a clinical-stage biopharmaceutical company focused on innovative treatments for chronic serious diseases with metabolic pathophysiology—including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders—has announced a significant…
UCB is A global biopharmaceutical leader committed to improving the lives of people living with severe diseases, highlighted its decade of growth and strategic priorities at the 43rd J.P. Morgan Healthcare Conference in San Francisco. For nearly a century, It…
MIREVO Japan’s 1st Neuropsychological Test for Dementia Treatment Now Available Otsuka Pharmaceutical and Ai-BrainScience Inc. have announced the launch of MIREVO®, a pioneering neuropsychological testing program designed to support medical treatment for dementia. As of January 1, 2025, MIREVO® has…
AbbVie and Simcere Zaiming Announce Partnership to Develop Novel Trispecific Antibody for Multiple Myeloma AbbVie a global leader in oncology and hematology, has joined forces with Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), to develop an…
Eli Lilly and Company has announced its preliminary revenue guidance for 2024 and 2025, showcasing significant growth and momentum in its operations. For 2024, Lilly anticipates full-year worldwide revenue to reach approximately $45.0 billion, representing an impressive 32% growth compared…
Pharma Partners Gilead and LEO Pharma Forge Strategic Partnership to Advance Oral STAT6 Program for Inflammatory Diseases Pharma Partners Gilead Sciences and LEO Pharma today announced a groundbreaking strategic partnership designed to accelerate the development and commercialization of LEO Pharma’s…